Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

阿尔茨海默症其新药研发失败率高达99.6%。昨天我们分享了两家失败的药物Simufilam和AL002，其 针对的靶点较为新颖。今日我们就其靶点和数据进行分析。

Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...

Cassava Sciences 陷入困境的阿尔茨海默病候选药物 simufilam 的开发似乎终于走到了尽头。 11月25日，这家总部位于德克萨斯州奥斯汀的生物技术公司透露 ...

Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results, but its ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.